In vitro activity of the histatin derivative P-113 against multidrug-resistant pathogens responsible for pneumonia in immunocompromised patients.

Abstract

The in vitro activity of the histatin derivative P-113, alone or combined with eight antibiotics, was investigated against multidrug-resistant strains isolated from clinical specimens of immunocompromised patients with pneumonia. The gram-negative isolates were susceptible to P-113. S. aureus showed less susceptibility. Synergy was demonstrated when P-113 was combined with beta-lactams against gram-negative organisms.

• Authors: Andrea Giacometti, Oscar Cirioni, Wojciech Kamysz, Giuseppina D'Amato, Carmela Silvestri, Maria Simona Del Prete, Alberto Licci, Alessandra Riva, Jerzy Lukasiak, Giorgio Scalise
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 49 Issue 3 Pg. 1249-52 (Mar 2005) ISSN: 0066-4804 [Print] United States
• PMID: 15728942 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Histatins
• P-113D
• Salivary Proteins and Peptides

Topics

• Drug Resistance, Multiple, Bacterial
• Histatins
• Humans
• Immunocompromised Host
• Microbial Sensitivity Tests
• Pneumonia, Bacterial (microbiology)
• Pseudomonas aeruginosa (drug effects)
• Salivary Proteins and Peptides (pharmacology)
• Staphylococcus aureus (drug effects)
• Stenotrophomonas maltophilia (drug effects)